Excision BioTherapeutics Stock

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.

Sign up today and learn more about Excision BioTherapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

Invest Now Sell Shares

About Excision BioTherapeutics Stock

Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.

Funding History

September 2017	$10.0M
December 2019	$750K
February 2021	$60.0M

Management

Board Member

Vasudev Bailey

Board Member

Ashok Krishnamurthi

CEO

Daniel Dombusch

CFO

Neal Kaplan

Interim Chief Business Officer

Michael Aberman

Principal Scientific Advisor

Khamel Khalili

Co-Founder

Rob Simmons

Press

patents - Apr, 14 2024

Computer-implemented systems and methods for targeting microhomology-mediated …

patents - Apr, 14 2024

Compositions and methods for excision with single grna

patents - Apr, 14 2024

Compositions and methods of treatment for lytic and lysogenic viruses

patents - Apr, 14 2024

Gene editing methods and compositions for eliminating risk of jc virus …

finance - Jan, 19 2024

HIV Type-1 Market is Likely to Increase at a Steady Growth ...

Trending Companies

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Join Now

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen Inc. was awarded a 2023 Fintech Breakthrough Award by Tech Breakthrough LLC on or about March 23, 2023, based on the prior calendar year and covering calendar year 2023, and has compensated Tech Breakthrough LLC for use of its name and logo in connection with the award. Tech Breakthrough LLC is a third party and has no affiliation with EquityZen.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2024 EquityZen Inc. All rights reserved.